Naklofen (Diclofenac Sodium)

Diclofenac sodium blocks the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, the drug reduces inflammation, pain signaling, and fever at the affected site.

The specific dose of Naklofen is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare professionals select the appropriate volume and concentration according to established medical guidelines.

Safety data for diclofenac sodium injection in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified prescriber.

To order Naklofen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Naklofen delivers diclofenac sodium via intramuscular injection, offering rapid onset compared with oral NSAIDs. Its potency is similar to other potent NSAIDs such as ibuprofen or naproxen, but the injectable route can be advantageous when oral administration is not feasible or when a quick therapeutic effect is required.

Naklofen should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight and extreme temperatures. Do not freeze the vial, and handle with aseptic technique to maintain sterility before intramuscular administration.

Naklofen is given by a single intramuscular injection into a large muscle, typically the gluteus or deltoid, by a qualified healthcare professional. The injection site should be cleaned with an antiseptic, and the volume administered according to the prescriber’s instructions.

Serious risks include gastrointestinal ulceration or bleeding, severe skin reactions such as Stevens‑Johnson syndrome, and acute kidney injury. Patients should be monitored for signs of abdominal pain, blood in stool, rash, or sudden changes in urine output, and seek medical attention promptly if these occur.

Naklofen is contraindicated in individuals with known hypersensitivity to diclofenac or other NSAIDs, those with active gastrointestinal ulceration, severe renal or hepatic impairment, and patients who have experienced a recent myocardial infarction or uncontrolled heart failure.